Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Product liability litigation

Executive Summary

Cases involving Robins Dalkon Shield and Merrell Dow's Bendectin accounted for nearly one-fifth of the increase in products liability filings in federal courts since the mid-1970s, the General Accounting Office maintained in a report to Rep. Florio (D-N.J.), whose House Commerce Subcommittee passed product liability legislation in December. A federal interagency Tort Policy Working Group headed by the Justice Department has reported that federal court filings increased by 758% from 1974-1985. GAO's analysis shows that Dalkon Shield cases accounted for 12% of the filings and Bendectin cases accounted for 5%; asbestos cases accounted for another 40% of the filings. GAO concluded that "data seem inconsistent with the contention that there is a rapidly accelerating growth in federal product liability filings across a wide range of products.

You may also be interested in...



Legal Notebook: Catalyst’s Suit vs. FDA Is Tossed, Avonex Patent Invalidity Verdict Is Reinstated

Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.

Naturopath Marketing Brain Defense Supplement Anticipates Support For Making TBI Claims

Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.

Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients

The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel